Returns At Huapont Life SciencesLtd (SZSE:002004) Appear To Be Weighed Down
Returns At Huapont Life SciencesLtd (SZSE:002004) Appear To Be Weighed Down
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Although, when we looked at Huapont Life SciencesLtd (SZSE:002004), it didn't seem to tick all of these boxes.
我們應該尋找哪些趨勢?我們想確定可以長期價值成倍增長的股票?通常,我們希望注意到增長的趨勢 返回 在資本使用率(ROCE)方面,除此之外,還在擴大 基礎 所用資本的比例。基本上,這意味着公司擁有可以繼續進行再投資的盈利計劃,這是複合機器的特徵。但是,當我們查看Huapont Life SciencesLtd(深圳證券交易所:002004)時,它似乎並沒有勾選所有這些方框。
What Is Return On Capital Employed (ROCE)?
什麼是資本使用回報率(ROCE)?
For those that aren't sure what ROCE is, it measures the amount of pre-tax profits a company can generate from the capital employed in its business. The formula for this calculation on Huapont Life SciencesLtd is:
對於那些不確定ROCE是什麼的人,它衡量的是公司從其業務中使用的資本中可以產生的稅前利潤金額。在 Huapont Life SciencesLtd 上進行此計算的公式爲:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
已動用資本回報率 = 息稅前收益 (EBIT) ¥(總資產-流動負債)
0.08 = CN¥1.6b ÷ (CN¥30b - CN¥10b) (Based on the trailing twelve months to September 2023).
0.08 = 16億元人民幣 ÷(30億元人民幣-10億元人民幣) (基於截至2023年9月的過去十二個月)。
So, Huapont Life SciencesLtd has an ROCE of 8.0%. In absolute terms, that's a low return, but it's much better than the Chemicals industry average of 6.0%.
因此,華邦生命科學有限公司的投資回報率爲8.0%。從絕對值來看,回報率很低,但比化工行業6.0%的平均水平要好得多。
Historical performance is a great place to start when researching a stock so above you can see the gauge for Huapont Life SciencesLtd's ROCE against it's prior returns. If you want to delve into the historical earnings , check out these free graphs detailing revenue and cash flow performance of Huapont Life SciencesLtd.
歷史表現是研究股票的絕佳起點,因此在上方您可以看到Huapont Life SciencesLtd的投資回報率與先前回報對比的指標。如果您想深入研究歷史收益,請查看這些免費圖表,詳細說明Huapont Life SciencesLtd的收入和現金流表現。
What The Trend Of ROCE Can Tell Us
ROCE 的趨勢能告訴我們什麼
In terms of Huapont Life SciencesLtd's historical ROCE trend, it doesn't exactly demand attention. The company has consistently earned 8.0% for the last five years, and the capital employed within the business has risen 25% in that time. This poor ROCE doesn't inspire confidence right now, and with the increase in capital employed, it's evident that the business isn't deploying the funds into high return investments.
就Huapont Life SciencesLtd的歷史投資回報率趨勢而言,這並不完全值得關注。在過去五年中,該公司的收入一直保持在8.0%,在此期間,公司內部使用的資本增長了25%。這種糟糕的投資回報率目前並不能激發信心,隨着所用資本的增加,很明顯,該企業沒有將資金部署到高回報的投資中。
In Conclusion...
總之...
In conclusion, Huapont Life SciencesLtd has been investing more capital into the business, but returns on that capital haven't increased. And in the last five years, the stock has given away 13% so the market doesn't look too hopeful on these trends strengthening any time soon. All in all, the inherent trends aren't typical of multi-baggers, so if that's what you're after, we think you might have more luck elsewhere.
總之,Huapont Life SciencesLtd一直在向該業務投入更多資金,但該資本的回報率並未增加。在過去的五年中,該股已經下跌了13%,因此市場對這些趨勢在短期內走強似乎並不抱太大希望。總而言之,多裝袋機的固有趨勢並不常見,因此,如果您想要這樣做,我們認爲您在其他地方可能會有更多的運氣。
Since virtually every company faces some risks, it's worth knowing what they are, and we've spotted 4 warning signs for Huapont Life SciencesLtd (of which 2 are a bit concerning!) that you should know about.
由於幾乎每家公司都面臨一些風險,因此值得了解它們是什麼,我們已經發現了Huapont Life SciencesLtd的4個警告信號(其中2個有點令人擔憂!)你應該知道的。
If you want to search for solid companies with great earnings, check out this free list of companies with good balance sheets and impressive returns on equity.
如果你想尋找收益豐厚的穩健公司,可以免費查看這份資產負債表良好且股本回報率可觀的公司名單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。